Cellulitis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Cellulitis}} | {{Cellulitis}} | ||
==Overview== | |||
==Future Therapies== | |||
{| style="border: 0px; font-size: 85%; margin: 3px;" align=center | |||
|+ | |||
! style="background: #4479BA; width: 120px;" | {{fontcolor|#FFF|}} | |||
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Chloroquine}} | |||
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Ribavirin}} | |||
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|6-Azauridine}} | |||
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Arbidol}} | |||
! style="background: #4479BA; width: 160px;" | {{fontcolor|#FFF|Harringtonine}} | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | Assay type | |||
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero cells) | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Human | |||
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero cells) | |||
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (vero and primary human fibroblast cells) | |||
| style="padding: 5px 5px; background: #F5F5F5;" |In vitro (BHK21 cells) | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | Hypothesized target | |||
| style="padding: 5px 5px; background: #F5F5F5;" | Disrupted endosome-mediated CHIKV internalization, possibly through the prevention of endosomal acidification. | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Can interact with the intracellular viral RNA production. | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Inhibition of orotidine monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine, cytidine, and thymidine. | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Inhibition of virus mediated fusion and blocking of the viral entry into the target cells through inhibition of glycoprotein conformational changes that are essential for the fusion process. | |||
| style="padding: 5px 5px; background: #F5F5F5;" |Affects CHIKV RNA production inside the infected cell as well as viral protein expression such as the nsP3 and the E2 proteins. | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | Advantages | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | Disadvantages | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
|- | |||
| style="padding: 5px 5px; background: #DCDCDC;" | References | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
| style="padding: 5px 5px; background: #F5F5F5;" | | |||
|- | |||
| style="padding: 5px 5px; background: #FFF;" colspan="6"| <SMALL>Table adapted from </SMALL> | |||
|- | |||
|} | |||
==References== | ==References== | ||
Line 11: | Line 62: | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
[[Category:Inflammations]] | [[Category:Inflammations]] | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 15:41, 18 June 2014
Cellulitis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cellulitis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Cellulitis future or investigational therapies |
Risk calculators and risk factors for Cellulitis future or investigational therapies |
Overview
Future Therapies
Chloroquine | Ribavirin | 6-Azauridine | Arbidol | Harringtonine | |
---|---|---|---|---|---|
Assay type | In vitro (vero cells) | Human | In vitro (vero cells) | In vitro (vero and primary human fibroblast cells) | In vitro (BHK21 cells) |
Hypothesized target | Disrupted endosome-mediated CHIKV internalization, possibly through the prevention of endosomal acidification. | Can interact with the intracellular viral RNA production. | Inhibition of orotidine monophosphate decarboxylase, an enzyme involved in the de novo biosynthesis of pyrimidine, cytidine, and thymidine. | Inhibition of virus mediated fusion and blocking of the viral entry into the target cells through inhibition of glycoprotein conformational changes that are essential for the fusion process. | Affects CHIKV RNA production inside the infected cell as well as viral protein expression such as the nsP3 and the E2 proteins. |
Advantages | |||||
Disadvantages | |||||
References | |||||
Table adapted from |